Healthcare >> CEO Interviews >> July 5, 2004
DR. WILLIAM CARTER has served as Chief Scientific Officer of Hemispherx
Biopharma, Inc., since May 1989, the Chairman of the company's Board of
Directors since January 1992, the company's Chief Executive Officer
since July 1993, the company's President since April 1995, and a
Director since 1987. He is the co-inventor of Ampligen', joined the
company in 1978, and from 1987 to 1988, he served as the company's
Chairman. Dr. Carter was a leading innovator in the development of human
interferon for a variety of treatment indications including various
viral diseases and cancer. In this context, he received the first FDA
approval to initiate clinical trials on a beta interferon product
manufactured in the US under his supervision. From 1985 to October 1988,
Dr. Carter served as the company's Chief Executive Officer and Chief
Scientist. He received his MD degree from Duke University and underwent
his post-doctoral training at the National Institutes of Health and
Johns Hopkins University. Dr. Carter also served as Professor of
Neoplastic Diseases at Hahnemann Medical University, a position he held
from 1980 to 1998. He also served as Director of Clinical Research for
Hahnemann Medical University's Institute for Cancer and Blood Diseases,
and as a Professor at Johns Hopkins School of Medicine and the State
University of New York at Buffalo. He is a Board certified physician and
author of more than 200 scientific articles, including the editing of
various textbooks on anti-viral and immune therapy. Profile
picture of things as they are now.
Dr. Carter: Hemispherx Biopharma is a biopharmaceutical company that has
been actively
